Notice of Proposed Sale · 144

Immunome, Inc.

IMNMNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Aug 12, 2026Accepted Aug 12, 2026, 11:40 AM EDTFiling CIK 1808343Accession 0001959173-26-005926

View company →Permanent SEC source ↗

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer: Immunome Inc.
Issuer CIK: 0001472012
SEC file number: 001-39580
Phone: 610-321-3700
Person for whose account securities are to be sold: Barchas Isaac
Relationships to issuer: Director
Street: 18702 N. CREEK PARKWAY
Street (continued): SUITE 100
City: BOTHELL
State / country code: WA
Postal code: 98011

Securities proposed for sale

Securities proposed for sale · 1 reported row
Security	Proposed units	Aggregate market value	Units outstanding	Approximate sale date	Exchange	Broker / market maker
Common	11,048	301,058.00	113,577,629	08/12/2026	NASDAQ	Fidelity Brokerage Services LLC

Broker / market maker — proposed row 1, entry 1

Name: Fidelity Brokerage Services LLC
Street: 900 Salem Street
City: Smithfield
State / country code: RI
Postal code: 02917

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
Security	Acquired	Nature of acquisition	Acquired from	Amount acquired	Gift transaction	Payment date	Nature of payment
Common	03/30/2026	Investment Distribution	Issuer	11,048	N	03/30/2026	Cash

Prior-sale reporting

Nothing to report for the preceding three months: Y

Notice signature

Notice date: 08/12/2026
Signed: /s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Isaac Barchas
Plan adoption dates: 03/31/2026

Company context

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; and IM-3050, a clinical-stage FAP-targeted radioligand therapy. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.

Current securities

IMNMNASDAQ · EQUITY · Current

Get the free weekly BCS email.